Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers

References

• RothGA, JohnsonC, AbajobirA, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. doi:10.1016/j.jacc.2017.04.05228527533
   PubMed Web of Science ®Google Scholar
• PiepoliMF, HoesAW, AgewallS, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. doi:10.1093/eurheartj/ehw10627222591
   PubMed Web of Science ®Google Scholar
• EatonCB, FeldmanHA, AssafAR, et al. Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension. J Fam Pract. 1994;38(1):17–23.8289046
   PubMed Web of Science ®Google Scholar
• JohnsonML, PietzK, BattlemanDS, BeythRJ. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care. 2004;10(12):926–932.15617368
   PubMed Web of Science ®Google Scholar
• DahlofB. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 2010;105(1 Suppl):3A–9A. doi:10.1016/j.amjcard.2009.10.007
   PubMedGoogle Scholar
• WlodarczykJ, SullivanD, SmithM. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol. 2008;102(12):1654–1662. doi:10.1016/j.amjcard.2008.08.01419064019
   PubMed Web of Science ®Google Scholar
• JamesPA, OparilS, CarterBL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520. doi:10.1001/jama.2013.28442724352797
   PubMed Web of Science ®Google Scholar
• ParkCG, YounHJ, ChaeSC, et al. Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, Phase II, multicenter study. Am J Cardiovasc Drugs. 2012;12(1):35–47. doi:10.2165/11597170-000000000-0000022217192
   PubMed Web of Science ®Google Scholar
• WilliamsB, ManciaG, SpieringW, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.30165516
   PubMed Web of Science ®Google Scholar
• BangaloreS, KamalakkannanG, ParkarS, MesserliFH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719. doi:10.1016/j.amjmed.2006.08.03317679131
   PubMed Web of Science ®Google Scholar
• DevabhaktuniM, BangaloreS. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag. 2009;5(1):377–387. doi:10.2147/vhrm.s333919475775
   PubMedGoogle Scholar
• World Health Organization Guidelines for registration of fixed-dose combination medicinal products. Available from: http://www.gmp-compliance.org/guidemgr/files/WHO_TRS_929_ANNEX5.PDF. Accessed 89, 2019.
   Google Scholar
• LeeHY, KimSY, ChoiKJ, et al. A randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and the tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with comorbid essential hypertension and hyperlipidemia. Clin Ther. 2017;39(12):2366–2379. doi:10.1016/j.clinthera.2017.10.01329150250
   PubMed Web of Science ®Google Scholar
• ChoiY, LeeS, ChoSM, et al. Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study. Drug Des Devel Ther. 2016;10:3021–3028. doi:10.2147/DDDT.S113891
   PubMed Web of Science ®Google Scholar
• OhM, GhimJL, ParkSE, KimEY, ShinJG. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of fimasartan, amlodipine, and rosuvastatin using partial replicated design in healthy adult subjects. Drug Des Devel Ther. 2018;12:1157–1164. doi:10.2147/DDDT.S164215
   PubMed Web of Science ®Google Scholar
• OhM, ShinJG, AhnS, et al. Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects. Drug Des Devel Ther. 2019;13:991–997. doi:10.2147/DDDT.S202730
   PubMed Web of Science ®Google Scholar
• SicaDA, GehrTW, GhoshS. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797–814. doi:10.2165/00003088-200544080-0000316029066
   PubMed Web of Science ®Google Scholar
• JiaJY, ZhangMQ, LiuYM, et al. Pharmacokinetics and bioequivalence evaluation of two losartan potassium 50-mg tablets: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. Clin Ther. 2010;32(7):1387–1395. doi:10.1016/j.clinthera.2010.06.01820678685
   PubMed Web of Science ®Google Scholar
• RohatagiS, LeeJ, ShenoudaM, et al. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J Clin Pharmacol. 2008;48(11):1309–1322. doi:10.1177/009127000832217618974285
   PubMed Web of Science ®Google Scholar
• McIntyreM, CaffeSE, MichalakRA, ReidJL. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther. 1997;74(2):181–194. doi:10.1016/S0163-7258(97)82002-59336021
   PubMed Web of Science ®Google Scholar
• MartinPD, WarwickMJ, DaneAL, CantariniMV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003;25(8):2215–2224. doi:10.1016/S0149-2918(03)80214-X14512129
   PubMed Web of Science ®Google Scholar